PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension

Yapeng Cao, Xiaoyu Zhang, Lina Wang, Qiuhua Yang, Qian Ma, Jiean Xu, Jingjing Wang, Laszlo Kovacs, Ramon J. Ayon, Zhiping Liu, Min Zhang, Yaqi Zhou, Xianqiu Zeng, Yiming Xu, Yong Wang, David J Fulton, Neal L. Weintraub, Rudolf Lucas, Zheng Dong, Jason X.J. YuanJennifer C Sullivan, Louise Meadows, Scott A. Barman, Chaodong Wu, Junmin Quan, Mei Hong, Yunchao Su, Yuqing Huo

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Increased glycolysis in the lung vasculature has been connected to the development of pulmonary hypertension (PH). We therefore investigated whether glycolytic regulator 6-phosphofructo-2-kinase/ fructose-2, 6-bisphosphatase (PFKFB3)-mediated endothelial glycolysis plays a critical role in the development of PH. Heterozygous global deficiency of Pfkfb3 protected mice from developing hypoxia-induced PH, and administration of the PFKFB3 inhibitor 3PO almost completely prevented PH in rats treated with Sugen 5416/hypoxia, indicating a causative role of PFKFB3 in the development of PH. Immunostaining of lung sections and Western blot with isolated lung endothelial cells showed a dramatic increase in PFKFB3 expression and activity in pulmonary endothelial cells of rodents and humans with PH. We generated mice that were constitutively or inducibly deficient in endothelial Pfkfb3 and found that these mice were incapable of developing PH or showed slowed PH progression. Compared with control mice, endothelial Pfkfb3-knockout mice exhibited less severity of vascular smooth muscle cell proliferation, endothelial inflammation, and leukocyte recruitment in the lungs. In the absence of PFKFB3, lung endothelial cells from rodents and humans with PH produced lower levels of growth factors (such as PDGFB and FGF2) and proinflammatory factors (such as CXCL12 and IL1β). This is mechanistically linked to decreased levels of HIF2A in lung ECs following PFKFB3 knockdown. Taken together, these results suggest that targeting PFKFB3 is a promising strategy for the treatment of PH.

Original languageEnglish (US)
Pages (from-to)13394-13403
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number27
DOIs
StatePublished - Jan 1 2019

Keywords

  • Endothelial cells
  • Glycolysis
  • Pulmonary hypertension

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension'. Together they form a unique fingerprint.

  • Cite this

    Cao, Y., Zhang, X., Wang, L., Yang, Q., Ma, Q., Xu, J., Wang, J., Kovacs, L., Ayon, R. J., Liu, Z., Zhang, M., Zhou, Y., Zeng, X., Xu, Y., Wang, Y., Fulton, D. J., Weintraub, N. L., Lucas, R., Dong, Z., ... Huo, Y. (2019). PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension. Proceedings of the National Academy of Sciences of the United States of America, 116(27), 13394-13403. https://doi.org/10.1073/pnas.1821401116